ESOPHAGEAL CANCER REVIEW ARTICLES
October 14, 2011 Although still relatively uncommon in Western countries, esophageal cancer is fatal in the vast majority of cases. In the United States, an estimated 16,640 new cases will be diagnosed in the year 2010, and 14,500 deaths will result from the disease. More »November 8, 2010 Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in the way these malignancies are managed. Although a relationship between gastroesophageal reflux disease and esophageal cancer has been demonstrated, antireflux surgery has been shown to have no preventive effect with regard to the development of esophageal adenocarcinoma. The newly modified staging system of the World Esophageal Cancer Consortium... More »November 8, 2010 Dr. Krasna has written an overview of multimodality therapy in esophageal cancer, with a particular focus on aspects related to staging and surgical care. The optimal management of locally advanced esophageal cancer remains a subject of controversy and active debate. However, there is now a clear consensus that surgery alone is inadequate therapy for patients with T3 or node-positive disease. More »September 2, 2010 Esophagitis is a known adverse effect of bisphosphonate use and reflux esophagitis is an established risk factor for esophageal cancer through the Barrett pathway. More »June 7, 2010 Meeting podcast: Listen to nationally regarded GI cancer specialist and clinical researcher, Peter C. Enzinger, MD, Assistant Professor of Medicine, Dana-Farber Cancer Institute, discuss new developments and trends in the management of esophageal cancer. More »March 9, 2010 Although still relatively uncommon in Western countries, esophageal cancer is fatal in the vast majority of cases. In the United States, an estimated 16,470 new cases will be diagnosed in the year 2009, and 14,530 deaths will result from the disease. This high percentage of deaths rivals that of pancreatic cancer and is more than four times that of rectal cancer. More »November 16, 2009 Turmeric, or curcumin (diferuloylmethane), may be a favorable agent for the prevention and treatment of esophageal cancer, according to researchers at the Cork Cancer Research Center and Mercy University Hospital in Cork, Ireland. The authors noted that turmeric was able to induce cell death by a mechanism that is not reliant on apoptosis induction. More »July 1, 2008 BARRX Medical, Inc, a global technology leader in treating Barrett's esophagus, announced the publication of two related European trials that report a 100% eradication rate for early esophageal cancer and precancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, the fastest growing cancer in the Western world. More »April 1, 2008 The use of neoadjuvant chemotherapy in resectable esophageal cancer was bolstered by the results of two trials presented at the 2008 Gastrointestinal Cancers Symposium. More »March 1, 2007 SEATTLE -- Aspirin and other NSAIDs decrease the risk of progression of the most aggressive form of Barrett's esophagus to esophageal cancer, researchers here reported. More »
Showing 1 - 10 of 31 results.
|
Improve EHR Systems by Rethinking Medical Billing Daniel Essin, MA, MD, February 6, 2012 Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
SEARCHMEDICA SEARCH RESULTS
Find peer-reviewed literature and websites for practicing medical professionals
|
Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in management.
